Abstract:Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL) and autologous stem cell transplant and more recently chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. Given these therapies are all associated with cardiovascular toxicities, patients with underlying cardiac co-morbidities are severely limited in treatment options. The focus of this review is to outline the cardiotoxicities associated with these standard treatments, explore strategies developed to mitigate these toxicities, and review novel treatment strategies for patients with underlying cardiovascular co-morbidities. DLBCL patients with underlying cardiac complications are a high-risk patient population who require complicated management strategies that utilize a multidisciplinary approach with collaboration between cardiologists and oncologists.
JACC CardioOncology Editor-in-Chief and CME EditorBonnie Ky, MD, MSCE, FACCAuthorBarbara S. Wiggins, PharmD, FACC
Date of Release: June 20, 2023Term of Approval/Date of CME/MOC Expiration: June 19, 2024